Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report
Hemophagocytic lymphohystiocytosis is an extremely life-threatening immune deregulatory syndrome. It is characterized by pathologic activation of immune cells, leading to excessive cytokine production, multiorgan failure, and potentially, death. A 28-year-old primigravida at 32 weeks and 3 days of g...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4889ee099ed84e398de5cc65078f9144 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:4889ee099ed84e398de5cc65078f9144 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:4889ee099ed84e398de5cc65078f91442021-11-24T04:34:47ZEpstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report2666-577810.1016/j.xagr.2021.100024https://doaj.org/article/4889ee099ed84e398de5cc65078f91442021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666577821000228https://doaj.org/toc/2666-5778Hemophagocytic lymphohystiocytosis is an extremely life-threatening immune deregulatory syndrome. It is characterized by pathologic activation of immune cells, leading to excessive cytokine production, multiorgan failure, and potentially, death. A 28-year-old primigravida at 32 weeks and 3 days of gestation presented with newly-diagnosed preeclampsia with severe features, fever, and fetal tachycardia. She was delivered by cesarean delivery. After delivery, she had a fever of unknown origin, with evidence of a hyperinflammatory state. Extensive infectious work-up was significant for positive Epstein-Barr Virus. A bone marrow biopsy demonstrated hemophagocytosis. She was diagnosed with Epstein-Barr-Virus-associated hemophagocytic lymphohystiocytosis and was treated with immunosuppression and chemotherapy. Hemophagocytic lymphohistiocytosis is a rare, life-threatening immune dysregulatory syndrome with both genetic and extragenic triggers that can occur in the postpartum period. Rituximab is an effective add-on therapy to conventional treatment.Bruce Lee, MDPeter Kouides, MDStephanie Bousquet, MDPaul Cabral, MDElsevierarticleEpstein-Barr virusfever of unknown originhemophagocytic lymphohistiocytosispostpartum preeclampsiaGynecology and obstetricsRG1-991ENAJOG Global Reports, Vol 1, Iss 4, Pp 100024- (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Epstein-Barr virus fever of unknown origin hemophagocytic lymphohistiocytosis postpartum preeclampsia Gynecology and obstetrics RG1-991 |
spellingShingle |
Epstein-Barr virus fever of unknown origin hemophagocytic lymphohistiocytosis postpartum preeclampsia Gynecology and obstetrics RG1-991 Bruce Lee, MD Peter Kouides, MD Stephanie Bousquet, MD Paul Cabral, MD Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
description |
Hemophagocytic lymphohystiocytosis is an extremely life-threatening immune deregulatory syndrome. It is characterized by pathologic activation of immune cells, leading to excessive cytokine production, multiorgan failure, and potentially, death. A 28-year-old primigravida at 32 weeks and 3 days of gestation presented with newly-diagnosed preeclampsia with severe features, fever, and fetal tachycardia. She was delivered by cesarean delivery. After delivery, she had a fever of unknown origin, with evidence of a hyperinflammatory state. Extensive infectious work-up was significant for positive Epstein-Barr Virus. A bone marrow biopsy demonstrated hemophagocytosis. She was diagnosed with Epstein-Barr-Virus-associated hemophagocytic lymphohystiocytosis and was treated with immunosuppression and chemotherapy. Hemophagocytic lymphohistiocytosis is a rare, life-threatening immune dysregulatory syndrome with both genetic and extragenic triggers that can occur in the postpartum period. Rituximab is an effective add-on therapy to conventional treatment. |
format |
article |
author |
Bruce Lee, MD Peter Kouides, MD Stephanie Bousquet, MD Paul Cabral, MD |
author_facet |
Bruce Lee, MD Peter Kouides, MD Stephanie Bousquet, MD Paul Cabral, MD |
author_sort |
Bruce Lee, MD |
title |
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
title_short |
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
title_full |
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
title_fullStr |
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
title_full_unstemmed |
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
title_sort |
epstein-barr virus-associated hemophagocytic lymphohistiocytosis in a postpartum patient with preeclampsia: a case report |
publisher |
Elsevier |
publishDate |
2021 |
url |
https://doaj.org/article/4889ee099ed84e398de5cc65078f9144 |
work_keys_str_mv |
AT bruceleemd epsteinbarrvirusassociatedhemophagocyticlymphohistiocytosisinapostpartumpatientwithpreeclampsiaacasereport AT peterkouidesmd epsteinbarrvirusassociatedhemophagocyticlymphohistiocytosisinapostpartumpatientwithpreeclampsiaacasereport AT stephaniebousquetmd epsteinbarrvirusassociatedhemophagocyticlymphohistiocytosisinapostpartumpatientwithpreeclampsiaacasereport AT paulcabralmd epsteinbarrvirusassociatedhemophagocyticlymphohistiocytosisinapostpartumpatientwithpreeclampsiaacasereport |
_version_ |
1718415909721210880 |